title: Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo.
abstract: Specific chromosomal abnormalities are independent predictors of response to therapy in acute nonlymphocytic leukemia (ANLL) de novo. In a series of 149 patients with ANLL, we sought to determine whether the t(8;21), t(15;17), t(9;11) or other abnormalities of the long arm of chromosome 11, inv(16) or t(16;16), inv(3) or t(3;3), trisomy 8, and abnormalities of chromosome 5 (-5/5q-) or of chromosome 7 (-7/7q-) identify differences in susceptibility to chemotherapy drugs in vivo. The immediate outcome of the first cycle of remission induction chemotherapy was analyzed for patients in each cytogenetic subgroup as an index of the drug susceptibility of the leukemia cells in vivo. Patients with t(8;21), inv(16), t(16;16), or 11q abnormalities had high rates of complete remission after initial therapy (60-100%), whereas patients with -7/7q- or -5/5q- had low initial response rates (0-36%), suggestive of drug resistance in vivo. In general, cytogenetic groups with high initial complete remission rates ("drug sensitive") also had long disease-free survivals; those groups with low initial remission rates ("drug resistant") had short remission durations even if these patients eventually achieved complete remission with further therapy. Patients with acute promyelocytic leukemia (APL), all of whom had the t(15;17), were the exception; despite low initial remission rates, they had long disease-free survivals, possibly due to a more rapid cytotoxic effect of chemotherapy on the clonogenic APL cells than on the more numerous malignant promyelocytes. We conclude that the prognostic importance of specific chromosomal abnormalities in ANLL resides in part in differing susceptibilities to chemotherapy.
authors.affiliation: Department of Medicine, University of Chicago, Illinois.
authors.forename: B L
authors.initials: BL
authors.lastname: Samuels
authors.forename: R A
authors.initials: RA
authors.lastname: Larson
authors.forename: M M
authors.initials: MM
authors.lastname: Le Beau
authors.forename: K M
authors.initials: KM
authors.lastname: Daly
authors.forename: M A
authors.initials: MA
authors.lastname: Bitter
authors.forename: J W
authors.initials: JW
authors.lastname: Vardiman
authors.forename: C M
authors.initials: CM
authors.lastname: Barker
authors.forename: J D
authors.initials: JD
authors.lastname: Rowley
authors.forename: H M
authors.initials: HM
authors.lastname: Golomb
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D002869:Chromosome Aberrations / Q000188:drug therapy / Q000235:genetics*; D025063:Chromosome Disorders; D004351:Drug Resistance; D006801:Humans; D007621:Karyotyping; D007938:Leukemia / Q000188:drug therapy / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction